Weight-loss drug leaders engage in pricing war

‍

Americans want Ozempic and other weight loss drugs, but not everyone can afford them.

‍

The $1,000-plus price tag on the branded versions of the drug has prompted millions of Americans to turn to lower-priced compounded versions and led many health plans to refuse coverage.

‍

Eli Lilly and Novo Nordisk, the pharmaceutical companies behind the popular injections, are cutting prices to help those paying out of pocket and encourage more health plans to begin paying for the medicine:

‍

• Lilly is now selling vials of its blockbuster weight-loss drug Zepbound to patients for as little as $399/month
• Novo Nordisk confirmed that the price of Ozempic after discounts is down 40% since the drug’s launch

‍

It’s still not a bargain, but if politicians get their way, prices will continue to decline in the coming months.

‍

The price war for weight-loss drugs is just getting started.